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Diana Kuh1, Yoav Ben-Shlomo5§, and Ken K. Ong6§
Objective: Randomized trials in men with testosterone deficiency have provided evidence of short-term
effects of testosterone therapy on muscle and fat mass but it is unclear whether this persists over a lon-
ger period or how testosterone affects women. We examined whether the midlife decline in testosterone
relates to fat and lean mass in both sexes.
Methods: Data were collected from 440 men and 560 women participating in the 1946 British birth
cohort study with testosterone measured at 53 and/or 60-64 years. Fat and appendicular lean mass were
measured at 60-64 years using dual-energy X-ray absorptiometry.
Results: Mean free testosterone concentrations were lower at 60-64 than 53 years, by 26% in both
sexes. At both ages testosterone was negatively associated with fat mass in men and positively associ-
ated in women. A larger decline in free testosterone was associated with higher fat mass in men but with
lower fat mass among women. In contrast, declines in testosterone were not associated with lean mass
in either sex.
Conclusions: Our findings suggest sex-divergent relationships between testosterone and fat mass and
their distribution but do not support the hypothesis that midlife declines in testosterone lead to lower
lean mass.
Obesity (2015) 23, 1486–1492. doi:10.1002/oby.21092
Introduction
Testosterone is known to have a number of important regulatory
roles in adults, and its decline observed during aging (1,2) may
adversely affect physical health and functioning via gains in fat and
losses in lean (muscle) mass (3,4). An evidence-based understanding
of the changes in testosterone that occur with aging—and the conse-
quences of these changes—is important, given recent trends in tes-
tosterone prescribing; among men in the UK and USA, there has
been an almost twofold and threefold increase in testosterone pre-
scription from 2001 to 2011, respectively (5,6).
Experimental studies have shown that testosterone supplementation
in men with low testosterone concentrations leads to gains in muscle
(7) and losses in fat mass (8,9). Conversely, diet- or bariatric sur-
gery-induced weight loss reverses the pathological suppression of
testosterone levels in overweight/obese men (10), suggesting a bi-
directional relationship between testosterone and fat mass. In con-
trast to these effects in men, rare reports of women undergoing sex
change therapy suggest that testosterone supplementation may
increase visceral fat mass (11). However, randomized trial evidence
is limited to interventions over 1-3 years in a small number of men
with testosterone deficiency. Thus, important questions remain as to
the longer term influence of testosterone for aging men and women
(12). Observational studies offer the advantage of studying differen-
ces in body composition in large numbers of subjects with wide var-
iations in testosterone levels, within individuals over long intervals.
However, previous observational studies have mostly been cross-
sectional, usually only of men, and yielded inconsistent results (13).
To the authors’ knowledge, this is the first study to prospectively
examine the associations between testosterone over a 10-year period
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with fat mass, fat distribution, and lean mass in late midlife simulta-
neously in both men and women. We hypothesized that testosterone
has a sexually dimorphic effect on fat but a monomorphic effect on
lean mass, so that decline in testosterone would be associated with
higher fat mass in men but lower fat mass in women and lower lean
mass in both sexes.
Methods
Study sample
The MRC National Survey of Health and Development (NSHD) is a
socially stratified sample of 5,362 singleton births during 1 week of
March 1946 in mainland Britain (14), with regular follow-up across life.
Between 2006 and 2010 (at 60-64 years), 2,856 eligible study members
(those known to be alive and with a known address in mainland Britain)
were invited for an assessment at one of six clinical research facilities
(CRFs) or to be visited by a research nurse at home. Invitations were not
sent to those who had died (n5 778), who were living abroad (n5 570),
who had previously withdrawn from the study (n5 594), or who had
been lost to follow-up (n5 564). Of those invited, 2,229 were assessed:
1,690 attended a CRF and the remaining 539 were seen at home (15).
The study received multicenter research ethics committee approval, and
informed consent was given by participants.
Body composition measurement
During CRF visits, body composition measures were obtained in the
supine position using a QDR 4500 Discovery dual-energy X-ray
absorptiometry (DXA) scanner (Hologic Inc, Bedford, MA, USA)
with APEX 3.1 software. Measures used as outcomes were whole
body fat mass (kg), a measure of fat distribution (android:gynoid
ratio (multiplied by 100); higher values indicating greater fat in the
abdominal (android) region relative to the hips (gynoid)), and appen-
dicular (limb) lean mass (kg)—1,558 participants had data available
for height and body composition outcomes, with missing data
largely due to high-density artifacts.
Blood sampling and testosterone measurement
At 53 years, nonfasting venous blood samples were obtained during
home visits from 2,750 participants in ethylenediaminetetraacetic acid
(EDTA) tubes in the morning (27%), afternoon (30%), or evening
(43%). These were then posted overnight to a laboratory where plasma
was extracted before being frozen at 280C. At 60-64 years, overnight
fasting venous blood samples were obtained in citrate tubes from 2,143
participants, in most cases in the morning (93% between 7.30 am and
10 am)—these were then taken immediately to a laboratory during CRF
visits, and plasma extracted before being frozen at280C.
Total testosterone and sex-hormone binding globulin (SHBG) were
measured in the same laboratory from plasma samples at 53 and 60-
64 years. Liquid chromatography-mass spectrometry (LC-MS/MS)
was used to measure testosterone (16,17), and immunoassay used
for SHBG (Abbott Diagnostics, Maidenhead, UK). Inter-assay coef-
ficients of variation were as follows: 4.7, 3.9, 4.3, 4.0, and 3.6% for
testosterone (at 0.9, 1.7, 4.3, 16.8, and 29.0 nmol/L), and 2.7, 5.0,
and 5.4% for SHBG (at 8.4, 22.4, and 136 nmol/L). A total of 1,000
participants had valid testosterone measures at both ages—missing
data were largely due to insufficient plasma following other bio-
chemical assays.
Analytical strategy
As taller individuals tend to have more fat and lean mass, height-
adjusted indices for fat and appendicular lean mass were created by
dividing fat and lean mass (kg) by height(m)X (X5 1.2 for fat and 2
for lean mass), where X was calculated so that the resulting index
was not correlated with height (18,19).
To preserve the analytic sample, values which fell below detection
limits (<0.3 nmol/L for testosterone) were replaced with a random
value between 0 and the detection limit (total N (irrespective of out-
come data)5 146 for testosterone (98% women). Values above
detection limits were truncated to the detection limit (250 nmol/L
for SHBG (N5 5)). To minimize the impact of outliers, six women
with high testosterone concentrations were truncated at 3 nmol/L—
the inclusion of original outlying values was found to bias regres-
sion coefficients. Free testosterone was calculated as described by
Vermeulen et al. (20)—an albumin constant (4.3g/L) was assumed
for all participants at 53 years, and measured albumin was used at
60-64 years.
Linear regression was used to examine associations between hor-
mones and body composition outcomes, separately for each sex. To
aid the comparability of effect sizes, hormone measures were con-
verted to sex-specific z-scores; measures at 53 and 60-64 years from
women were log-transformed before this as distributions were posi-
tively skewed. Outcomes were log transformed and multiplied by
100—regression coefficients therefore show the mean percentage dif-
ference in outcome per 1 standard deviation increase in testosterone.
We tested for potential sex differences in associations by including an
interaction term. We also assessed models with testosterone catego-
rized in quintiles to examine for any departures from linearity.
Samples at 53 years we taken either in the morning, afternoon or
evening, unlike morning blood samples at 60-64 years. We took into
account diurnal variability in testosterone (higher concentrations in
the morning) by running sex-specific regression models with testos-
terone at 53 years as the outcome and time of blood collection as a
categorical exposure. The residuals from this model were then added
to mean morning testosterone concentration for those who gave
blood samples in the afternoon and evening.
We firstly tested associations between testosterone and our outcomes
cross-sectionally (60-64 years) and prospectively (53 years). We
then ran conditional change models by including the change in hor-
mone from 53 to 60-64 adjusting for hormone concentration at 53
years. Complete case analyses were used in all regression analyses;
of the 1,000 participants with valid testosterone measures at both
ages, 200 had missing body composition outcome data because they
did not attend the CRF at 60-64 years, and 19 had missing data for
potential confounders, leaving an analytic sample of 781.
Potential confounders
Associations with lean mass could be confounded by fat mass, as
due to adaptive mechanisms changes in fat mass typically lead to
respective changes in lean mass (21). We therefore examined lean
mass without and with adjustment for fat mass index. Models ana-
lyzing change in testosterone were further adjusted for additional
potential confounders selected a-priori: highest household occupa-
tional class, smoking status, self-rated health (reported number of
health problems from 0-5) and menopausal status at 53 years
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(categorized as pre-, peri- or post-menopausal (5.4, 14.3, and 28.7%
of the total sample respectively), hysterectomy (23.4%) or other
operation stopping periods (6.0%), and a further 22.1% could not be
classified because they started taking HRT before the menopause, as
described elsewhere (22).
Supplementary analyses
To examine the possibility of reverse or bi-directionality, change mod-
els for fat mass were repeated with additional adjustment for body mass
index (BMI) at age 53, and further analyses conducted in which BMI
(or change in BMI) was the exposure, and testosterone the outcome. To
examine the extent to which adjustment for time of blood sampling
affected findings, analyses were repeated with no adjustment for time
of blood sample; analyses were also repeated restricted to those with
morning blood samples at both 53 and 60-64 years (before 10am at 60-
64 years; total N5 219). To examine whether truncation of testosterone
among the six participants with outlying values impacted on findings,
analyses were repeated excluding these participants. To examine the
extent to which analyses of change were non-linear, analyses were
repeated using change score variables converted into quartiles.
Results
Descriptive analyses
Men had greater android fat mass, android:gynoid ratio and appen-
dicular lean mass, whilst women had a larger fat mass index and
gynoid fat mass (P< 0.02 in all cases). As expected, mean total and
free testosterone were higher in men than women, while women had
higher SHBG concentrations (P< 0.001 in all cases). In both sexes,
mean testosterone concentrations declined from 53 to 60-64 years
(by approximately 22% among men, and 35% among women).
Mean free testosterone also declined (by approximately 26% among
men, and 26% among women), while SHBG slightly increased in
men and declined in women. There were moderate correlations
between total and free testosterone at 53 and 60-64 suggesting some
tracking of hormone concentrations (r5 0.66 and r5 0.40 in men,
r5 0.44 and r5 0.49 in women, respectively; P< 0.001 in all
cases). Those with missing testosterone data at 60-64 years differed
in some respects in their hormone concentrations at 53 years—on
average men with missing data at 60-64 years had higher total tes-
tosterone (P5 0.03) and SHBG (P5 0.01) concentrations at 53
years, but there were no significant differences in free testosterone
among either sex. At 53 years, women who were post-menopausal
had lower total testosterone (P(trend)5 0.02) and lower SHBG
(P(trend)5 0.01) than pre or peri-menopausal women but there was
no difference in free testosterone (P(trend)5 0.58).
Testosterone and fat mass
Among men, higher total and free testosterone concentrations at
both 53 and 60-64 years were associated with lower fat mass at 60-
64 years (Table 2; categorical analyses shown in Supporting Infor-
mation Table S1). Unlike men, women with higher testosterone at
53 years and 60-64 years had higher fat mass, though in the latter
confidence intervals overlapped with the null (Table 2 and
TABLE 1 Summary of body composition and testosterone concentrations by sex
Men Women
Mean (SD or IQR) Mean (SD)
Hormone concentration, age N5 440 N5 560
Testosterone (nmol/L), 53 16.2 (4.9) 0.9 (0.4)
Testosterone (nmol/L), 60–64 12.6 (4.7) 0.6 (0.3)
D Testosterone 23.6 (26.0, 1.3)a 20.3 (20.5, 20.1)a
Sex-hormone binding globulin (nmol/L), 53 34.2 (14.0) 65.0 (40.6)
Sex-hormone binding globulin (nmol/L), 60–64 36.4 (14.5) 49.4 (26.2)
D Sex-hormone binding globulin 2.2 (23.9, 7.8)a 215.6 (226.3, 4.4)a
Calculated free testosterone (pmol/L), 53 325.0 (81.8) 11.9 (7.9)
Calculated free testosterone (pmol/L), 60–64 240.1 (68.8) 8.8 (6.0)
D Calculated free testosterone 285.0 (2141.0, 234.1)a 23.1 (25.5, 0.1)a
Body composition at 60–64 years N5 746 N5 812
Fat mass index (kg/m1.2) 12.0 (3.6) 16.2 (5.0)
Android fat mass (kg) 2.5 (1.0) 2.3 (1.0)
Gynoid fat mass (kg) 3.7 (1.0) 5.1 (1.4)
Android:gynoid ratio 65.16 (15.5) 44.9 (12.0)
Appendicular lean mass index (kg/m2) 8.0 (1.0) 6.2 (0.9)
Body mass index 27.7 (3.9) 27.5 (5.0)
Body mass index at 53 years N5 989 N5 1110
27.2 (3.8) 27.1 (5.1)
aP< 0.001, comparison between ages using paired t-tests; free testosterone calculated according to Vermeulen et al.20; estimated morning testosterone concentrations
used at 53 years; analyses restricted to participants with valid data for all body composition outcomes or all hormone measures at both ages.
Body mass index at 53 years calculating using the sample with valid body mass index data for 60–64 years.
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Supporting Information Table S1; sex interaction tests all P< 0.05).
Higher SHBG at both ages was associated with lower fat mass in
both sexes—more strongly in women than men. Associations
between these exposures with android:gynoid ratio and BMI at 60-
64 years (Supporting Information Table S2) were generally similar
to those with fat mass.
As predicted, greater declines in total and free testosterone
between 53 and 60-64 years were associated with higher fat mass
and higher android:gynoid ratio among men (see negative coeffi-
cients in Table 2). In contrast, greater declines in free testosterone
were associated with lower fat mass and android:gynoid ratio
among women, while total testosterone was not associated. The
magnitude of these associations was large for men. In adjusted
models, a 1 standard deviation greater decline in free testosterone
was associated with 11% higher fat mass in men and 4% lower fat
mass in women. In both sexes, greater declines in SHBG (or,
equivalently, lesser gains in SHBG) were associated with higher
fat mass and android:gynoid ratio. Associations were similar after
adjustment for potential confounders, and for BMI at 53 years
(Supporting Information Table S3).
Testosterone and appendicular lean mass
Neither total nor free testosterone at 53 or 60-64 years were associ-
ated with appendicular lean mass at 60-64 years in men (Table 3).
Among women, higher free testosterone at both ages was associated
with higher lean mass. In both sexes higher SHBG (at both ages)
was associated with lower lean mass.
Contrary to our predictions, there was little evidence that changes in
total or free testosterone were associated with lean mass in either
sex either before or after adjustment for fat mass (Table 3). How-
ever, greater declines in SHBG were associated with were associated
with higher lean mass, both before and after adjustment for potential
confounders.
Additional and sensitivity analyses
Greater gains in BMI from 53 to 60-64 years were associated with
lower testosterone concentrations at 60-64 years among men (but
not women), and greater gains in BMI were weakly (nonsignifi-
cantly) associated with lower free testosterone in men, and higher
free testosterone among women (Supporting Information Table S4).
TABLE 2 Mean percentage differences in fat mass and android:gynoid fat mass ratio (95% CI) at 60–64 years per 1 standard
deviation increase in serum testosterone concentration at 53 and 60–64 years
Men (N5 345) P Women (N5 436) P P sex interaction
Fat mass index
Testosterone, 53 26.75 (210.17, 23.32) <0.001 4.57 (1.65, 7.49) <0.01 <0.001
Testosterone, 60–64 210.77 (213.78, 27.75) <0.001 2.31 (20.45, 5.07) 0.10 <0.001
D Testosterone 29.96 (213.35, 26.56) <0.001 0.47 (23.10, 4.04) 0.80 <0.01
D Testosterone, adjusteda 29.54 (213.03, 26.06) <0.001 1.19 (22.43, 4.80) 0.52 <0.01
SHBG, 53 24.59 (28.17, 21.00) 0.01 29.11 (211.96, 26.26) <0.001 0.04
SHBG, 60–64 25.43 (28.58, 22.28) <0.001 213.39 (216.14, 210.64) <0.001 <0.001
D SHBG 23.85 (27.21, 20.49) 0.02 213.21 (216.93, 29.50) <0.001 <0.01
D SHBG, adjusteda 23.20 (26.66, 0.26) 0.07 211.67 (215.53, 27.82) <0.001 <0.01
Free testosterone, 53 25.43 (28.58, 22.28) <0.001 9.51 (6.77, 12.25) <0.001 <0.001
Free testosterone, 60–64 25.12 (28.39, 21.86) <0.01 8.39 (5.74, 11.03) <0.001 <0.001
D Free testosterone 211.54 (215.58, 27.50) <0.001 3.63 (0.40, 6.87) 0.03 <0.001
D Free testosterone, adjusteda 211.31 (215.42, 27.21) <0.001 3.98 (0.80, 7.15) 0.01 <0.001
Android:gynoid fat mass ratio
Testosterone, 53 23.42 (26.19, 20.66) 0.02 3.29 (0.63, 5.95) 0.02 0.003
Testosterone, 60–64 26.67 (29.14, 24.19) <0.001 1.66 (20.85, 4.17) 0.19 <0.001
D Testosterone 26.84 (29.63, 24.06) <0.001 0.72 (22.54, 3.98) 0.67 <0.01
D Testosterone, adjusteda 26.41 (29.24, 23.57) <0.001 1.79 (21.57, 5.14) 0.30 <0.01
SHBG, 53 24.55 (27.40, 21.70) <0.01 28.86 (211.43, 26.28) <0.001 0.88
SHBG, 60–64 25.87 (28.35, 23.39) <0.001 213.46 (215.90, 211.02) <0.001 0.34
D SHBG 24.57 (27.21, 21.93) <0.001 213.76 (217.05, 210.47) <0.001 <0.01
D SHBG, adjusteda 24.10 (26.81, 21.39) <0.01 211.90 (215.39, 28.41) <0.001 <0.01
Free testosterone, 53 20.36 (23.00, 2.28) 0.79 8.36 (5.86, 10.86) <0.001 0.01
Free testosterone, 60–64 24.06 (26.66, 21.47) <0.01 6.95 (4.53, 9.37) <0.001 <0.001
D Free testosterone 25.51 (28.88, 22.15) <0.01 4.20 (1.26, 7.14) <0.01 <0.001
D Free testosterone, adjusteda 25.07 (28.47, 21.66) <0.01 4.79 (1.86, 7.73) <0.01 <0.001
D standard deviation change between 53 and 60–64 years—analyses adjusted for hormone concentration at 53 years (e.g. D testosterone adjusted for testosterone at 53
years).
aAdjusted for highest household occupational class, smoking, self-rated health, and menopausal status at 53 years.
SHBG: sex-hormone binding globulin; free testosterone calculated according to Vermeulen et al.; estimated morning testosterone concentrations used at 53 years.
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Findings were similar when not adjusting for time of blood collec-
tion at 53 years, when restricting analyses to participants with morn-
ing blood samples, or when excluding participants with outlying tes-
tosterone values. Finally, there was little evidence for nonlinearity in
the change models.
Discussion
In this representative British birth cohort study, marked declines in
total and free testosterone were observed during late midlife (53 to 60-
64 years) in both men and women. Larger declines in free testosterone
were associated with higher fat mass among men, yet lower fat mass
among women at 60-64 years. There was little evidence linking
declines in testosterone with lean mass in either men or women.
Our data add significantly to previous evidence linking testosterone
to body composition outcomes—existing observational studies have
mostly been cross-sectional, conducted in men, and yielded equivo-
cal findings (13,23,24). The NSHD enabled the investigation of var-
iations in testosterone and SHBG across the entire male and female
population distribution and their relationships to DXA body compo-
sition measures. The repeat measures obtained also enabled the lon-
gitudinal investigation of how age-related declines in these hor-
mones related to body composition outcomes.
Sex differences in the relationships between free testosterone and
body fat mass may reflect sex differences in the physiological role
of testosterone, and/or differences in upstream factors that drive tes-
tosterone concentrations. Among men with low testosterone concen-
trations, supplementation lowers fat mass levels (7,8), while rare
reports of women undergoing sex change therapy indicate that sup-
plementation increases visceral but lowers subcutaneous at (11). In
addition, polycystic ovary syndrome is typically characterized by
high testosterone concentrations and is associated with higher fat
mass. Little is currently known about the physiological roles of tes-
tosterone among women. There is emerging evidence (albeit from
cross-sectional studies) that higher endogenous testosterone is
related to adverse cardiometabolic health in women (25), despite
beneficial relationships with other outcomes such as bone mineral
density (24). Sex differences could also be driven by the down-
stream products of testosterone such as estrogen—in postmenopausal
women, circulating estrogen is mostly derived from peripheral con-
version of androgens, and fat cells are known to contain estrogen
receptors. However, hormone replacement therapy in postmeno-
pausal women reduces abdominal fat mass (26), suggesting that the
impacts of estrogen are unlikely to explain the positive associations
found between testosterone and fat mass. Further research is clearly
needed to better understand the sex differences in relations between
testosterone, estrogen and fat mass.
Associations between testosterone and fat mass were similar when
adjusting for an earlier indicator of fat mass (BMI at 53 years), sug-
gesting that reverse causality is unlikely to fully explain these find-
ings. However, associations between testosterone and fat mass are
likely to be bi-directional—weight loss have been found to lead to
higher testosterone in men (10), yet lower testosterone in women
(27). In support of this direction of association, as also found in in
other studies (28,29). Greater gains in BMI across midlife were
associated with lower testosterone concentrations among men. Dis-
entangling which direction of association predominates using obser-
vational data is likely to be challenging. One previous study com-
pared the magnitude of the testosterone-body weight association in
women with that of the reverse direction (body weight-testosterone)
to infer which direction of association was most likely (30). How-
ever, this inference may not be appropriate as regression dilution
would result in a weaker magnitude of association between exposure
and outcome when the exposure is measured less precisely (i.e., for
testosterone (assessed using immuno-assay) rather than weight).
We found little evidence linking declines in testosterone with lean
mass, in contrast to evidence from experimental studies
TABLE 3 Mean percentage differences in appendicular lean mass (95% CI) at 60–64 years per 1 standard deviation increase in
serum testosterone concentration at 53 and 60–64 years
Men (N5 345) P Women (N5436) P P sex interaction
Testosterone, 53 20.39 (21.57, 0.78) 0.51 20.18 (21.20, 0.84) 0.73 0.50
Testosterone, 60–64 20.40 (21.53, 0.74) 0.49 0.27 (20.68, 1.22) 0.58 0.19
D Testosterone 20.22 (21.48, 1.03) 0.73 0.43 (20.81, 1.67) 0.49 0.50
D Testosterone, adjusteda 20.39 (21.66, 0.89) 0.55 0.57 (20.71, 1.85) 0.38 0.32
SHBG, 53 21.42 (22.62, 20.23) 0.02 21.81 (22.86, 20.76) <0.001 0.82
SHBG, 60–64 21.60 (22.66, 20.55) <0.01 22.53 (23.63, 21.44) <0.001 0.93
D SHBG 21.06 (22.18, 0.06) 0.06 22.06 (23.48, 20.63) <0.01 0.05
D SHBG, adjusteda 21.24 (22.39, 20.10) 0.03 21.76 (23.25, 20.26) 0.02 0.17
Free testosterone, 53 0.45 (20.66, 1.56) 0.42 0.97 (20.06, 2.00) 0.07 0.27
Free testosterone, 60–64 0.74 (20.42, 1.89) 0.21 1.16 (0.18, 2.13) 0.02 0.34
D Free testosterone 0.78 (20.70, 2.27) 0.30 0.62 (20.55, 1.79) 0.30 0.51
D Free testosterone, adjusteda 0.74 (20.76, 2.25) 0.33 0.71 (20.49, 1.91) 0.24 0.38
All models are adjusted for fat-free mass index; D standard deviation change between 53 and 60–64 years—analyses adjusted for hormone concentration at 53 years
(e.g., D testosterone adjusted for testosterone at 53 years).
aAdjusted for highest household occupational class, smoking, self-rated health, and menopausal status at 53 years.
SHBG: sex-hormone binding globulin; free testosterone calculated according to Vermeulen et al.; estimated morning testosterone concentrations used at 53 years.
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demonstrating anabolic effects of testosterone (7-9). A possible
explanation for this difference is that the current study analysed var-
iations in testosterone across the physiological range, whereas the
effects of testosterone administration on lean mass are typically per-
formed in older men with hypogonadal testosterone levels. In addi-
tion, testosterone may be more strongly associated with the active
tissue components of lean mass (contractile muscle fibers), which
DXA does not distinguish from other components such as intra and
extra-cellular fluid (31). Most trials assess short-term benefits usu-
ally for no more than 1 year (32), while our results over a decade
may be influenced by other factors that attenuate these short-term
effects. Lower testosterone has been found to be related to greater
age-related decline change in lean mass (among men that lost
weight) (33), suggesting that testosterone may be especially impor-
tant for the processes which underlie this change—this warrants
future investigation in cohorts with repeat data. The null findings
presented here do not preclude the importance of testosterone for
muscle development during early-life growth.
SHBG was inversely associated with fat mass and android:gynoid
ratio in both men and women. This could suggest that SHBG has a
role in regulating fat mass levels. In support of this, SHBG genetic
variations conferring higher SHBG concentrations have been associ-
ated with lower risk of type-2 diabetes (34), which is thought to be
partly determined by fat mass levels. Much like associations
between testosterone and fat mass, associations with SHBG are
likely to be bi-directional, as higher fat mass levels would be associ-
ated with insulin resistance and therefore higher insulin concentra-
tions, which in turn down-regulates SHBG (35). This is demon-
strated in intervention studies which have found weight loss results
in higher SHBG (36). SHBG was also inversely associated with lean
mass—future studies should consider whether SHBG has any plausi-
ble physiological role in muscle mass regulation, or may be a useful
biomarker to indicate muscle mass levels.
Strengths of this study include the repeat measures of testosterone
ascertained in late midlife, a period during which the expected
decline with age was observed. Despite blood samples being col-
lected across mainland Britain, standard protocols were used and
testosterone assays at both ages were assessed in a single laboratory
using LC-MS/MS, which provides accurate testosterone measures
even at low concentrations (16,17). Other strengths include the sam-
pling of both sexes, precise and detailed measures of regional and
whole fat and lean mass, and availability of data for potential
confounders.
Limitations of this study include the lack of repeat DXA measures
of fat and lean mass, which precluded the investigation of how tes-
tosterone relates to change in these masses; however, our sensitivity
analyses using repeat BMI measures suggest that the findings are
likely to be similar. As in all longitudinal studies, attrition occurred
which limited statistical power and may have introduced bias (if the
associations investigated differed in the group lost to follow-up).
Blood samples were only taken once at each age and although single
measures of testosterone have been found to accurately reflect long-
term concentrations (37), multiple measures at more than two ages
may better characterize change in testosterone with age. Finally,
methodological differences likely affected the estimation of decline
in testosterone: at 53 years, nonfasting samples were used (38), and
samples were frozen for longer periods, with a longer delay before
being frozen—these likely resulted in an underestimation of testos-
terone at this age, and therefore its decline. Finally, blood samples
were taken throughout the day at 53 years but primarily during the
morning at 60-64 years. However, blood sample timing was
accounted for in analyses, and similar results were also found when
restricting analyses to participants with morning blood samples at
both ages.
While the findings from this study suggest that higher testosterone
concentrations may have favorable effects on body composition in
older men, these do not directly support the pharmacological raising
of testosterone levels which may have adverse consequences for car-
diovascular health. While one meta-analysis found testosterone sup-
plementation did not relate to cardiovascular risk (39), a subsequent
meta-analysis found that oral (but not injection or transdermal)
administration was related to increased cardiovascular risk (40).
Ongoing trials (32) which will compare (in men with low testoster-
one) the relative benefits of testosterone supplementation for a num-
ber of health-related outcomes. Alternative strategies that focus on
up-stream determinants of testosterone (such as early life or behav-
ior) may potentially lessen age-related decline and in turn could
limit the accumulation of fat mass and losses in lean mass that occur
during aging. Further research is clearly needed to identify the mod-
ifiable determinants of testosterone and its decline with age.
Conclusion
Our findings suggest sex-divergent relationships between testoster-
one and fat mass and their distribution but do not support the
hypothesis that midlife declines in testosterone lead to lower lean
mass. Further prospective observational and experimental studies are
required to strengthen causal inferences and investigate the possible
adverse cardiometabolic effects of testosterone in women.O
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